看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 8.9x - 9.8x | 9.3x |
| Selected Fwd Ps Multiple | 7.8x - 8.6x | 8.2x |
| Fair Value | ₹1,920 - ₹2,122 | ₹2,021 |
| Upside | -30.2% - -22.9% | -26.5% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Lupin Limited | 50,025,700.0% | BSE:500257 |
| Alembic Pharmaceuticals Limited | 53,357,300.0% | BSE:533573 |
| Medico Remedies Limited | 54,093,700.0% | BSE:540937 |
| Zydus Lifesciences Limited | 53,232,100.0% | BSE:532321 |
| Glenmark Pharmaceuticals Limited | 53,229,600.0% | BSE:532296 |
| GlaxoSmithKline Pharmaceuticals Limited | - | NSEI:GLAXO |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |||
| BSE:500257 | BSE:533573 | BSE:540937 | BSE:532321 | BSE:532296 | NSEI:GLAXO | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 6.4% | 9.6% | 8.2% | 8.2% | 5.1% | 2.0% | ||
| 3Y CAGR | 9.7% | 4.9% | 5.8% | 10.7% | 4.9% | 5.7% | ||
| Latest Twelve Months | 12.9% | 4.9% | 14.7% | 16.9% | 6.1% | 11.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 3.0% | 12.3% | 4.0% | 18.1% | 3.5% | 20.9% | ||
| Prior Fiscal Year | 2.6% | 6.1% | 5.2% | 11.4% | -1.5% | 18.7% | ||
| Latest Fiscal Year | 9.6% | 9.9% | 5.7% | 19.6% | -15.0% | 17.1% | ||
| Latest Twelve Months | 13.0% | 9.4% | 5.9% | 20.4% | -1.4% | 23.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 35.4x | 18.2x | 39.6x | 14.1x | 12.7x | 41.4x | ||
| Price / LTM Sales | 8.2x | 2.6x | 3.2x | 3.9x | 2.8x | 12.6x | ||
| LTM P/E Ratio | 62.7x | 27.5x | 55.1x | 19.3x | -194.2x | 54.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 2.6x | 3.2x | 8.2x | |||||
| Historical LTM P/S Ratio | 6.6x | 7.7x | 9.9x | |||||
| Selected Price / Sales Multiple | 8.9x | 9.3x | 9.8x | |||||
| (x) LTM Sales | 37,046 | 37,046 | 37,046 | |||||
| (=) Equity Value | 328,445 | 345,732 | 363,018 | |||||
| (/) Shares Outstanding | 169.4 | 169.4 | 169.4 | |||||
| Implied Value Range | 1,938.80 | 2,040.85 | 2,142.89 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 1,938.80 | 2,040.85 | 2,142.89 | 2,751.10 | ||||
| Upside / (Downside) | -29.5% | -25.8% | -22.1% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |
| Value of Common Equity | 1,797,999 | 166,568 | 4,874 | 873,663 | 388,728 | 466,053 | |
| (/) Shares Outstanding | 913.1 | 196.6 | 83.0 | 1,006.2 | 282.2 | 169.4 | |
| Implied Stock Price | 1,969.05 | 847.40 | 58.74 | 868.25 | 1,377.55 | 2,751.10 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1,969.05 | 847.40 | 58.74 | 868.25 | 1,377.55 | 2,751.10 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |